Log In
BCIQ
Print this Print this
 

GX-E2

  Manage Alerts
Collapse Summary General Information
Company Genexine Inc.
DescriptionFc-fused human erythropoietin (EPO)
Molecular Target Erythropoietin (EPO)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase II
Standard IndicationAnemia
Indication DetailsTreat anemia
Regulatory Designation
PartnerGreen Cross Corp.;
Shanghai Fosun Pharmaceutical Group Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$44.5M

0

$44.5M


 Deals Details
Get a free BioCentury trial today